On 2026-09-10, HSBC raised its LLY price target to $940 from $850 (+10.6%).
HSBC 于 2026-09-10 将 LLY 目标价上调至 $940，此前为 $850，变动幅度 +10.6%。
For information only. Not investment advice.内容仅供参考，不构成投资建议。
LLY receives FDA approval for InluriyoEli Lilly and Company（LLY）的 Inluriyo 获美国 FDA 批准
Material Company Event · September 18, 2026公司公告 · 2026/9/18
Guggenheim raises LLY target to $1,284Guggenheim 上调目标价 礼来 (LLY) 至 $1,284
Rating Change · September 18, 2026评级变动 · 2026/9/18
LLY regulatory decision: FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetesEli Lilly and Company（LLY）的 产品 获美国 FDA 许可或批准
Material Company Event · August 28, 2026公司公告 · 2026/8/28
